186 related articles for article (PubMed ID: 27833144)
1. Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis.
Lu S; Zhang Y; Zhou X; Zhou D; Yang Q; Ju B; Zhao X; Hu Z; Xie H; Zhou L; Zheng S; Wang W
Sci Rep; 2016 Nov; 6():36944. PubMed ID: 27833144
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Ueno M; Okusaka T; Omuro Y; Isayama H; Fukutomi A; Ikeda M; Mizuno N; Fukuzawa K; Furukawa M; Iguchi H; Sugimori K; Furuse J; Shimada K; Ioka T; Nakamori S; Baba H; Komatsu Y; Takeuchi M; Hyodo I; Boku N
Ann Oncol; 2016 Mar; 27(3):502-8. PubMed ID: 26681680
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
[TBL] [Abstract][Full Text] [Related]
7. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
Zhong S; Qie S; Yang L; Yan Q; Ge L; Wang Z
Medicine (Baltimore); 2017 Jul; 96(30):e7611. PubMed ID: 28746215
[TBL] [Abstract][Full Text] [Related]
8. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
9. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
[TBL] [Abstract][Full Text] [Related]
10. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
[TBL] [Abstract][Full Text] [Related]
11. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
[TBL] [Abstract][Full Text] [Related]
12. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
Huang PW; Chang CF; Hung CY; Hsueh SW; Chang PH; Yeh KY; Chen JS; Chen YY; Lu CH; Hung YS; Chou WC
Cancer Med; 2019 Sep; 8(12):5554-5563. PubMed ID: 31385456
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Xu Y; Guo X; Fan Y; Wang D; Wu W; Wu L; Liu T; Xu B; Feng Y; Wang Y; Lou W; Zhou Y
Jpn J Clin Oncol; 2018 Jun; 48(6):535-541. PubMed ID: 29718363
[TBL] [Abstract][Full Text] [Related]
14. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ioka T; Komatsu Y; Mizuno N; Tsuji A; Ohkawa S; Tanaka M; Iguchi H; Ishiguro A; Kitano M; Satoh T; Yamaguchi T; Takeda K; Kida M; Eguchi K; Ito T; Munakata M; Itoi T; Furuse J; Hamada C; Sakata Y
Br J Cancer; 2017 Feb; 116(4):464-471. PubMed ID: 28081543
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
Imaoka H; Kou T; Tanaka M; Egawa S; Mizuno N; Hijioka S; Hara K; Yazumi S; Shimizu Y; Yamao K
Eur J Cancer; 2016 Feb; 54():96-103. PubMed ID: 26741729
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Jin SF; Fan ZK; Pan L; Jin LM
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
Takashima A; Morizane C; Ishii H; Nakamura K; Fukuda H; Okusaka T; Furuse J
Jpn J Clin Oncol; 2010 Dec; 40(12):1189-91. PubMed ID: 20630899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
